Immunostimulatory effects of melphalan and usefulness in adoptive cell therapy with antitumor CD4+ t cells

Michal Kuczma, Zhi-Chun Ding, Gang Zhou

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The alkylating agent melphalan is used in the treatment of hematological malignancies, especially multiple myeloma. In the past, the usefulness of melphalan has been solely attributed to its cytotoxicity on fastgrowing cancerous cells. Although the immunomodulatory effects of melphalan were suggested many years ago, only recently has this aspect of melphalan’s activity begun to be elucidated at the molecular level. Emerging evidence indicates that melphalan can foster an immunogenic microenvironment by inducing immunogenic cell death (ICD) as characterized by membrane translocation of endoplasmic reticulum protein calreticulin (CRT) and by release of chromatin-binding protein high-mobility group box 1 (HMGB1). In addition, the lympho-depletive effect of melphalan can induce the release of pro-inflammatory cytokines and growth factors, deplete regulatory T cells, and create space to facilitate the expansion of infused tumor-reactive T cells. These features suggest that melphalan can be used as a preparative chemotherapy for adoptive T-cell therapy. This notion is supported by our recent work demonstrating that the combination of melphalan and adoptive transfer of tumor-reactive CD4+ T cells can mediate potent antitumor effects in animal models. This review summarizes the recent advances in understanding and utilizing the immunomodulatory effects of melphalan.

Original languageEnglish (US)
Pages (from-to)179-191
Number of pages13
JournalCritical Reviews in Immunology
Volume36
Issue number2
DOIs
StatePublished - Jan 1 2016

Fingerprint

Melphalan
Cell- and Tissue-Based Therapy
T-Lymphocytes
Calreticulin
Adoptive Transfer
Alkylating Agents
Hematologic Neoplasms
Regulatory T-Lymphocytes
Multiple Myeloma
Endoplasmic Reticulum
Chromatin
Neoplasms
Intercellular Signaling Peptides and Proteins
Carrier Proteins
Cell Death
Animal Models
Cytokines
Drug Therapy
Membranes

Keywords

  • Adoptive cell therapy
  • CD4
  • Immunostimulation
  • Melphalan

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immunostimulatory effects of melphalan and usefulness in adoptive cell therapy with antitumor CD4+ t cells. / Kuczma, Michal; Ding, Zhi-Chun; Zhou, Gang.

In: Critical Reviews in Immunology, Vol. 36, No. 2, 01.01.2016, p. 179-191.

Research output: Contribution to journalArticle

@article{e28d4b5428fd453aa173b77343c13106,
title = "Immunostimulatory effects of melphalan and usefulness in adoptive cell therapy with antitumor CD4+ t cells",
abstract = "The alkylating agent melphalan is used in the treatment of hematological malignancies, especially multiple myeloma. In the past, the usefulness of melphalan has been solely attributed to its cytotoxicity on fastgrowing cancerous cells. Although the immunomodulatory effects of melphalan were suggested many years ago, only recently has this aspect of melphalan’s activity begun to be elucidated at the molecular level. Emerging evidence indicates that melphalan can foster an immunogenic microenvironment by inducing immunogenic cell death (ICD) as characterized by membrane translocation of endoplasmic reticulum protein calreticulin (CRT) and by release of chromatin-binding protein high-mobility group box 1 (HMGB1). In addition, the lympho-depletive effect of melphalan can induce the release of pro-inflammatory cytokines and growth factors, deplete regulatory T cells, and create space to facilitate the expansion of infused tumor-reactive T cells. These features suggest that melphalan can be used as a preparative chemotherapy for adoptive T-cell therapy. This notion is supported by our recent work demonstrating that the combination of melphalan and adoptive transfer of tumor-reactive CD4+ T cells can mediate potent antitumor effects in animal models. This review summarizes the recent advances in understanding and utilizing the immunomodulatory effects of melphalan.",
keywords = "Adoptive cell therapy, CD4, Immunostimulation, Melphalan",
author = "Michal Kuczma and Zhi-Chun Ding and Gang Zhou",
year = "2016",
month = "1",
day = "1",
doi = "10.1615/CritRevImmunol.2016017507",
language = "English (US)",
volume = "36",
pages = "179--191",
journal = "Critical Reviews in Immunology",
issn = "1040-8401",
publisher = "Begell House Inc.",
number = "2",

}

TY - JOUR

T1 - Immunostimulatory effects of melphalan and usefulness in adoptive cell therapy with antitumor CD4+ t cells

AU - Kuczma, Michal

AU - Ding, Zhi-Chun

AU - Zhou, Gang

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The alkylating agent melphalan is used in the treatment of hematological malignancies, especially multiple myeloma. In the past, the usefulness of melphalan has been solely attributed to its cytotoxicity on fastgrowing cancerous cells. Although the immunomodulatory effects of melphalan were suggested many years ago, only recently has this aspect of melphalan’s activity begun to be elucidated at the molecular level. Emerging evidence indicates that melphalan can foster an immunogenic microenvironment by inducing immunogenic cell death (ICD) as characterized by membrane translocation of endoplasmic reticulum protein calreticulin (CRT) and by release of chromatin-binding protein high-mobility group box 1 (HMGB1). In addition, the lympho-depletive effect of melphalan can induce the release of pro-inflammatory cytokines and growth factors, deplete regulatory T cells, and create space to facilitate the expansion of infused tumor-reactive T cells. These features suggest that melphalan can be used as a preparative chemotherapy for adoptive T-cell therapy. This notion is supported by our recent work demonstrating that the combination of melphalan and adoptive transfer of tumor-reactive CD4+ T cells can mediate potent antitumor effects in animal models. This review summarizes the recent advances in understanding and utilizing the immunomodulatory effects of melphalan.

AB - The alkylating agent melphalan is used in the treatment of hematological malignancies, especially multiple myeloma. In the past, the usefulness of melphalan has been solely attributed to its cytotoxicity on fastgrowing cancerous cells. Although the immunomodulatory effects of melphalan were suggested many years ago, only recently has this aspect of melphalan’s activity begun to be elucidated at the molecular level. Emerging evidence indicates that melphalan can foster an immunogenic microenvironment by inducing immunogenic cell death (ICD) as characterized by membrane translocation of endoplasmic reticulum protein calreticulin (CRT) and by release of chromatin-binding protein high-mobility group box 1 (HMGB1). In addition, the lympho-depletive effect of melphalan can induce the release of pro-inflammatory cytokines and growth factors, deplete regulatory T cells, and create space to facilitate the expansion of infused tumor-reactive T cells. These features suggest that melphalan can be used as a preparative chemotherapy for adoptive T-cell therapy. This notion is supported by our recent work demonstrating that the combination of melphalan and adoptive transfer of tumor-reactive CD4+ T cells can mediate potent antitumor effects in animal models. This review summarizes the recent advances in understanding and utilizing the immunomodulatory effects of melphalan.

KW - Adoptive cell therapy

KW - CD4

KW - Immunostimulation

KW - Melphalan

UR - http://www.scopus.com/inward/record.url?scp=84994403320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994403320&partnerID=8YFLogxK

U2 - 10.1615/CritRevImmunol.2016017507

DO - 10.1615/CritRevImmunol.2016017507

M3 - Article

VL - 36

SP - 179

EP - 191

JO - Critical Reviews in Immunology

JF - Critical Reviews in Immunology

SN - 1040-8401

IS - 2

ER -